neuren responds, page-31

Neuren (NEU) 10c
THE influence of social media has been tested in a novel way: advocacy of a drug that's in phase two clinical trials but far from gaining regulatory approval.
Yesterday Neuren was forced to respond to a petition on the Change.org forum, which included comments from parents of clinical trial candidates afflicted by the genetic neurological disorder Rett syndrome.
The parents claimed their daughters underwent dramatic improvement when administered with the compound NNZ-2566.
The trouble is, some of the 60 candidates were taking a placebo. Because of the double-blinded nature of the trial, no one will know who was taking what until the results are released in the second half of 2014.
The petition urges the Food & Drug Administration to expedite approval of the drug, which already has fast-track status.
But Neuren said the comments reflected "subjective impressions that have not been validated by analysis of clinical data".
Neuren shares have run hard and the stock commands a $120m valuation, but something tells us there's more. Spec buy.
[email protected]